KSR 592
Latest Information Update: 16 Jul 2016
Price :
$50 *
At a glance
- Originator Kissei Pharmaceutical
- Class Antiasthmatics; Glucocorticoids; Small molecules
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Asthma
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Asthma in Japan (Inhalation)
- 26 May 2001 Profile reviewed but no significant changes made
- 30 Apr 1998 Preclinical development for Asthma in Japan (Inhalation)